Ceftriaxone Sodium Injection, Powder, For Solution
NDC Package 0781-3210-46

11-digit billing NDC: 00781321046 · Billing unit: EA · 1 EA per package
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Ceftriaxone Sodium injection is before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Sandoz Inc, this product is identified by NDC 0781-3210 and is authorized under FDA application ANDA065168.

Identification & Billing

NDC Package Code
0781-3210-46
Package Description
1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON / 100 mL in 1 VIAL, PHARMACY BULK PACKAGE
Product Code
0781-3210
11-Digit Billing Format
00781321046
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 309090 - cefTRIAXone 100 MG/ML Injectable Solution
  • RxCUI: 309090 - ceftriaxone 100 MG/ML Injectable Solution
  • RxCUI: 309090 - ceftriaxone (as ceftriaxone sodium) 10 GM per 100 ML Injectable Solution
  • RxCUI: 309090 - ceftriaxone (as ceftriaxone sodium) 100 GM per 1000 ML Injectable Solution

Clinical Specifications

Proprietary Name
Ceftriaxone Sodium
Non-Proprietary Name
Ceftriaxone Sodium
Substance Name
Ceftriaxone Sodium
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
CEFTRIAXONE SODIUM 10 g/100mL
Pharmacologic Class
Usage Information
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms:

Regulatory & Marketing

Labeler Name
Sandoz Inc
Product Type
Human Prescription Drug
FDA Application #
ANDA065168
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-17-2005
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0696
Source: ASP
Ceftriaxone sodium injection
HCPCS Dosage 250 MG
Units / Pkg 40

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0781-3210-46 identifies a specific commercial package of 1 vial, pharmacy bulk package in 1 carton / 100 ml in 1 vial, pharmacy bulk package of Ceftriaxone Sodium, a human prescription drug labeled by Sandoz Inc. This injection, powder, for solution is formulated for intravenous use and contains ceftriaxone sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sandoz Inc on May 17, 2005. The current certification is valid through December 31, 2027.

How is this Sandoz Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00781321046. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0781-3210-46
11-Digit CMS (5-4-2)
00781-3210-46

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.